NCT03863457 |
[18F] F-GLN by PET/CT in Breast Cancer |
NCT05304962 |
First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer |
NCT04360330 |
SABER Study for Selected Early Stage Breast Cancer |
NCT02926729 |
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy |
NCT03861975 |
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening |
NCT05504707 |
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer |
NCT03765983 |
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases |
NCT05074290 |
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients |
NCT04651452 |
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors |
NCT05051631 |
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity |
NCT05978960 |
EXERT-BCN: An Exercise and Nutrition Regimen to Designed to Improve Body Composition After Treatment for Breast Cancer |
NCT05821244 |
Exercise Timing in Breast Cancer Patients |
NCT05931874 |
Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors |
NCT03212170 |
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer |
NCT03761706 |
Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging |
NCT05968157 |
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick |
NCT06229392 |
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer |
NCT05505643 |
Cryoablation vs Lumpectomy in T1 Breast Cancers |
NCT04270149 |
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer |
NCT05378464 |
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer |
NCT06052488 |
Strength After Breast Cancer |
NCT03742245 |
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
NCT05810025 |
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments |
NCT05950945 |
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
NCT03694756 |
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer |
NCT06133348 |
Promoting Resilience in Women With Breast Cancer |
NCT04768426 |
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer |
NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
NCT05464667 |
Preoperative Irradiation for Stage I Breast Cancer |
NCT04965064 |
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling |
NCT05755984 |
3D Printed Breast Models in the Surgical Management of Breast Cancer |
NCT06081127 |
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function |
NCT05334732 |
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters) |
NCT06121453 |
Adherence Intervention in Patients With Metastatic Breast Cancer |
NCT05766891 |
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery |
NCT05625659 |
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts |
NCT05483283 |
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care |
NCT05623488 |
CAR T Cells in Mesothelin-Expressing Breast Cancer |
NCT06361056 |
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials |
NCT05659797 |
FES BPET-DBT in Newly Diagnosed Breast Cancer |
NCT04013568 |
Exercise Post-Diagnosis of Breast Cancer |
NCT04914663 |
All-extremity Exercise During Breast Cancer Chemotherapy |
NCT03643861 |
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI) |
NCT05609435 |
Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer |
NCT05984888 |
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer |
NCT05704842 |
Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy |
NCT05665660 |
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening |
NCT05130840 |
Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer |
NCT03025035 |
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer |
NCT05615753 |
Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors |
NCT06127979 |
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery |
NCT04756765 |
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer |
NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer |
NCT05417451 |
Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors |
NCT05675579 |
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) |
NCT05856773 |
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy |
NCT03272334 |
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer |
NCT05636943 |
Couples' QOL in Metastatic Breast Cancer |
NCT05633979 |
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer |
NCT05838417 |
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study |
NCT06085742 |
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer |
NCT04493034 |
Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer |
NCT04594473 |
A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors |
NCT05957042 |
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI). |
NCT03400215 |
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer |
NCT03820141 |
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer |
NCT05042687 |
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer |
NCT04040569 |
A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer |
NCT05259410 |
Time Restricted Eating During Chemotherapy for Breast Cancer |
NCT05243641 |
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test |
NCT04354675 |
Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer |
NCT05933395 |
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor |
NCT03712813 |
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors |
NCT04796220 |
Focused Ultrasound and Gemcitabine in Breast Cancer |
NCT02958774 |
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation |
NCT05528133 |
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer |
NCT06027268 |
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer |
NCT06100874 |
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) |
NCT01035112 |
Magnetic Resonance Imaging of Breast Cancer |
NCT04990921 |
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer |
NCT03824145 |
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer |
NCT05716516 |
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) |
NCT04243616 |
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer |
NCT05305924 |
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer |
NCT05959291 |
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer |
NCT04523857 |
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer |
NCT04891068 |
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer |
NCT02807597 |
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment |
NCT04020575 |
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) |
NCT05748834 |
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer |
NCT04332588 |
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI |
NCT02732171 |
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer |
NCT04968964 |
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing |
NCT06019988 |
Effect of Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer |
NCT04427293 |
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) |
NCT05187832 |
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer |
NCT04450706 |
Functional Precision Oncology for Metastatic Breast Cancer |
NCT04273555 |
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging |
NCT04364672 |
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
NCT05130801 |
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery |
NCT06239467 |
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
NCT04568616 |
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
NCT04542135 |
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer |
NCT05318469 |
Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer |
NCT03043794 |
Study of Stereotactic Radiotherapy for Breast Cancer |
NCT06026657 |
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer |
NCT04573231 |
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer |
NCT05233800 |
mHealth for Breast Cancer Survivors With Insomnia |
NCT05101564 |
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer |
NCT05700396 |
Breast Cancer Survivor Educational Intervention |
NCT04965688 |
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition |
NCT06228768 |
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer |
NCT03801369 |
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer |
NCT05806138 |
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction |
NCT05374915 |
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) |
NCT05676255 |
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project |
NCT05472792 |
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) |
NCT05574686 |
Telemonitoring Hypertension and Breast Cancer |
NCT05867667 |
Cardiac Rehabilitation to Improve Breast Cancer Outcomes |
NCT04458532 |
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer |
NCT06274034 |
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors |
NCT04074720 |
Prospective Breast Cancer Biospecimen Collection |
NCT05013255 |
Pioglitazone Therapy Targeting Fatigue in Breast Cancer |
NCT05553522 |
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
NCT05859971 |
ICG and SLN Mapping |
NCT05812924 |
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause |
NCT03779867 |
Acute Exercise Intervention in Breast Cancer Survivors |
NCT06219434 |
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer |
NCT05787834 |
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer |
NCT05132296 |
Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer |
NCT04267796 |
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women |
NCT04378751 |
Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer |
NCT04721886 |
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer |
NCT04913064 |
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer |
NCT05325151 |
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer |
NCT05325632 |
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
NCT05928325 |
Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment |
NCT06115486 |
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer |
NCT03945721 |
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
NCT04720209 |
Taking AIM at Breast Cancer |
NCT05408260 |
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer |
NCT04824027 |
Breast Elasticity Imaging During Neoadjuvant Chemotherapy |
NCT06072807 |
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer |
NCT04674306 |
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer |
NCT03439735 |
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC |
NCT06139107 |
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole |
NCT05288777 |
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer |
NCT06006806 |
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy |
NCT06260332 |
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors |
NCT05524584 |
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer |
NCT05150652 |
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer |
NCT05826964 |
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
NCT03729115 |
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer |
NCT05595499 |
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors |
NCT06006299 |
Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) |
NCT05660083 |
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) |
NCT04174352 |
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
NCT05193149 |
Inspiratory Muscle Training in Obese Breast Cancer Survivors |
NCT03955627 |
REJOIN Trial for Older Breast Cancer Survivors |
NCT06028022 |
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors |
NCT06086704 |
Study of 18F-FFNP Breast PET/MRI |
NCT06258993 |
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation |
NCT03847311 |
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients |
NCT05386719 |
Cardiometabolic Screening Program |
NCT05756166 |
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer |
NCT06055803 |
Heart Health After Cancer Treatment (HEART-ACT) |
NCT04454528 |
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy |
NCT06042569 |
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial |
NCT05376878 |
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis |
NCT04493333 |
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors |
NCT05069038 |
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy |
NCT05703178 |
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia |
NCT04365569 |
Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program |
NCT04923542 |
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
NCT04724499 |
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy |
NCT04265872 |
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
NCT04998682 |
Prospective Evaluation of Targeted Axillary Dissection (TAD) |
NCT04636710 |
Refining Local-Regional Therapy for IBC |
NCT04315233 |
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics |
NCT06245889 |
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC |
NCT04983342 |
Apollo Device for Metastatic Breast Cancer (MBC) |
NCT06145399 |
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer |
NCT05447910 |
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT04379414 |
YES Study - Newly Diagnosed/Metastatic Intervention |
NCT05710328 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial |
NCT02802553 |
Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions |
NCT02476786 |
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
NCT03285412 |
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
NCT05444231 |
Breaking Through the Brain Fog: An Online Research Study |
NCT04703920 |
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer |
NCT05505045 |
Metacognitive Strategy Training in Cancer-related Cognitive Impairment |
NCT06008158 |
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer |
NCT05464082 |
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC |
NCT05786014 |
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies |
NCT04614194 |
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib |
NCT05219695 |
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) |
NCT06136923 |
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer |
NCT04973930 |
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer |
NCT04088708 |
Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors |
NCT04521764 |
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer |
NCT04727632 |
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial |
NCT05996107 |
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer |
NCT05560685 |
SMART-ER: Symptom Monitoring With Patient-reported Outcomes |
NCT03769415 |
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA |
NCT04563507 |
Combined Immunotherapies in Metastatic ER+ Breast Cancer |
NCT06085833 |
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions |
NCT05746325 |
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer |
NCT06057636 |
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study |
NCT01984138 |
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy |
NCT02290834 |
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer |
NCT04233385 |
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery |
NCT04648904 |
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer |
NCT03995082 |
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey |
NCT05846789 |
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers |
NCT05704283 |
3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer |
NCT05340673 |
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer |
NCT04986579 |
Scalp Cooling in MBC |
NCT06185205 |
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy |
NCT04120246 |
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer |
NCT04871139 |
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer |
NCT05452681 |
A QoL Intervention for Young African American Breast Cancer Survivors |
NCT05456373 |
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery |
NCT05394259 |
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer |
NCT06153836 |
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction |
NCT03983577 |
Efficacy of Point Of Service Testing in MBC |
NCT06193070 |
An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information |
NCT05591547 |
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr |
NCT04049214 |
Perioperative Mindfulness Proposal |
NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
NCT04030507 |
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer |
NCT05983380 |
The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors |
NCT05674578 |
Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors |
NCT05243056 |
A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer |
NCT04692818 |
3D Ultrasound Breast Imaging |
NCT04791384 |
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer |
NCT04290897 |
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors |
NCT04754412 |
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study |
NCT05049746 |
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy |
NCT04717050 |
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity |
NCT04849871 |
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma |
NCT03941756 |
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer |
NCT05298605 |
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women |
NCT05095207 |
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer |
NCT05825482 |
Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout® |
NCT04348747 |
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
NCT05677802 |
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer |
NCT04445844 |
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
NCT06328738 |
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
NCT06176261 |
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs |
NCT03796559 |
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes |
NCT04205903 |
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer |
NCT04090567 |
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
NCT04715958 |
Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation |
NCT05319873 |
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
NCT05975736 |
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening |
NCT05226663 |
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer |
NCT06067503 |
Biomarkers to Detect Endocrine Therapy Resistance |
NCT03897270 |
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects |
NCT05716542 |
Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial) |
NCT03216421 |
Intraoperative Radiation Therapy (IORT) in DCIS |
NCT05020860 |
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
NCT05417308 |
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer |
NCT05245812 |
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy |
NCT05491226 |
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation |
NCT06129747 |
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast |
NCT05256745 |
RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer |
NCT04677816 |
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients |
NCT02946697 |
A Culturally Sensitive Social Support Intervention |
NCT03449238 |
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients |
NCT05608252 |
VS-6766+Abema+Fulv in Met HR+/HER- BC |
NCT05565534 |
Diabetes Care for Breast Cancer Patients |
NCT03213041 |
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer |
NCT05535192 |
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients |
NCT04959474 |
SABR-CaRe in Early Stage Breast Cancer |
NCT05693766 |
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort |
NCT05557877 |
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer |
NCT05501704 |
ETHAN - ET for Male BC |
NCT05269160 |
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ) |
NCT03796273 |
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases |
NCT04305834 |
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. |
NCT04837209 |
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer |
NCT05468034 |
Exercise in Metastatic Breast Cancer: EMBody |
NCT05684367 |
Exercise to ReGain Stamina and Energy (The EXERGISE Study) |
NCT05098210 |
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer |
NCT06220214 |
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer |
NCT05645471 |
Together After Cancer |
NCT02095184 |
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients |
NCT06188559 |
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer |
NCT05142358 |
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose |
NCT05036096 |
Cone Beam Breast CT for Breast Cancer Screening |
NCT03546686 |
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer |
NCT04443413 |
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients |
NCT02422641 |
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis |
NCT04234386 |
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer |
NCT05230810 |
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. |
NCT05455658 |
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer |
NCT04906200 |
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors |
NCT05954143 |
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer |
NCT03671044 |
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients |
NCT04862585 |
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel |
NCT05868187 |
CanRestoreFunction Cancer-related Fatigue ( CRF ) |
NCT04993313 |
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study |
NCT06058650 |
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities |
NCT02760030 |
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery |
NCT04329065 |
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer |
NCT05464810 |
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
NCT05412953 |
Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain |
NCT05368428 |
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer |
NCT05251714 |
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer |
NCT04009044 |
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast |
NCT06169371 |
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) |
NCT04946864 |
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer |
NCT05853848 |
Mammogram Mail- and Phone-based Interventions |
NCT05807074 |
Impact of Topical Tranexamic Acid in Breast Reconstruction |
NCT05774678 |
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation |
NCT05754749 |
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
NCT05744557 |
Vapocoolant Analgesia for Breast Lymphoscintigraphy |
NCT05731791 |
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation |
NCT02926690 |
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer |
NCT05496829 |
IMPACT Trial: Intervention to iMProve AdherenCe Equitably |
NCT03715959 |
Nipple Aspirate Fluid in Detecting Breast Cancer |
NCT05291507 |
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System |
NCT05206331 |
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study |
NCT05181722 |
Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic |
NCT04534010 |
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts |
NCT06171607 |
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses |
NCT04348123 |
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography |
NCT04258280 |
Improving Genetic Counseling for BRCA+ Mothers |
NCT04225572 |
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT) |
NCT04175639 |
mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients |
NCT03321045 |
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
NCT03238976 |
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy |
NCT05637216 |
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients |
NCT05809752 |
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) |
NCT03953157 |
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors |
NCT06018337 |
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) |
NCT05056844 |
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge |
NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
NCT04333706 |
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) |
NCT05960188 |
Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images |
NCT06275126 |
Optimizing Surgical Decisions in Young Adults With Breast Cancer |
NCT04815083 |
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery |
NCT05316324 |
A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction |
NCT05223322 |
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction |
NCT05892068 |
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain |
NCT05314179 |
Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community |
NCT05190978 |
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction |
NCT06082882 |
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2 |
NCT05020574 |
Microbiome and Association With Implant Infections |
NCT05226078 |
The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients |
NCT04965246 |
Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors |
NCT03909282 |
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma |
NCT04904757 |
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening |
NCT06295744 |
Outcomes and Cosmesis With Whole Breast Irradiation and Boost |
NCT03979508 |
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer |
NCT05841355 |
Empowering Latinas to Obtain Guideline Concordant Screenings |
NCT05289466 |
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation. |
NCT05795101 |
TRUDI: TDXD+Durva in HER2+/Low IBC |
NCT05935891 |
A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma) |
NCT06072612 |
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
NCT05488145 |
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy |
NCT04225585 |
Well-Being After Breast Cancer Surgery |
NCT05414812 |
Intervening on Women's Health for Rural Young Breast Cancer Survivors |
NCT05780814 |
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer |
NCT03990896 |
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial |
NCT04252859 |
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma |
NCT03934905 |
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction |
NCT05978128 |
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants |
NCT05309655 |
Cardiac Outcomes With Near-Complete Estrogen Deprivation |
NCT02918474 |
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer |
NCT06253182 |
Psychosexual Educational Partners Program (PEPP) |
NCT02400060 |
Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer |
NCT05190770 |
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
NCT05654532 |
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer |
NCT05912231 |
Ultrahypofractionation and Normal Tissue Toxicity |
NCT05351424 |
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc |
NCT06136884 |
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors |
NCT05023967 |
Metformin and Nightly Fasting in Women With Early Breast Cancer |
NCT04886531 |
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers |
NCT05921253 |
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy |
NCT05694559 |
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics |
NCT05014295 |
Patient Recall of Cancer Screening and Diagnosis |
NCT04806724 |
Opening the Conversation Study |
NCT04136912 |
3-D Super Resolution Ultrasound Microvascular Imaging |
NCT04371913 |
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study |
NCT04175210 |
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) |
NCT05383196 |
Onvansertib + Paclitaxel In TNBC |
NCT05585788 |
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients |
NCT05305365 |
Study Assessing QBS72S For Treating Brain Metastases |
NCT04722341 |
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators |
NCT05746897 |
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors |
NCT05111561 |
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
NCT05655598 |
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer |
NCT02484404 |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... |
NCT05554211 |
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage |
NCT05607017 |
Losartan in Prevention of Radiation-Induced Heart Failure |
NCT04872166 |
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer |
NCT03709446 |
Leflunomide in Previously Treated Metastatic Triple Negative Cancers |
NCT06105749 |
Biennial CEM in Women With a Personal History of Breast Cancer |
NCT05327452 |
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study |
NCT01185132 |
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
NCT05528263 |
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) |
NCT04821141 |
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens |
NCT05458674 |
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC |
NCT02927912 |
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
NCT05627960 |
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies |
NCT04003038 |
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery |
NCT04248257 |
Peer Support For Young Adult Women With High Breast Cancer Risk |
NCT03696030 |
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases |
NCT05029999 |
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer |
NCT03747120 |
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab |
NCT06125145 |
Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study |
NCT05323409 |
Improving Comprehensive Care of Cancer Patients |
NCT04533373 |
Sensory Restoration After DIEP Flap Neurotization |
NCT06096623 |
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment |
NCT05649072 |
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. |
NCT05700669 |
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors |
NCT04230109 |
Sacituzumab Govitecan In TNBC |
NCT05078398 |
Postoperative Opt-In Narcotics Treatment in Breast |
NCT05563220 |
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
NCT05607004 |
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
NCT06257758 |
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors |
NCT04407611 |
Scalable Communication Modalities for Returning Genetic Research Results |
NCT04711824 |
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
NCT06206837 |
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. |
NCT05573555 |
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) |
NCT05596409 |
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study |
NCT06216574 |
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial |
NCT04567420 |
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT05498155 |
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer |
NCT05412225 |
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer |
NCT05909397 |
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer |
NCT06150664 |
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies |
NCT05774951 |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
NCT04699630 |
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer |
NCT05966584 |
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer |
NCT04841148 |
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer |
NCT05132582 |
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer |
NCT06103864 |
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
NCT06112379 |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
NCT05548127 |
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) |
NCT05629585 |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) |
NCT04862663 |
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) |
NCT04072952 |
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
NCT05374512 |
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) |
NCT06125522 |
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) |
NCT05501886 |
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) |
NCT05654623 |
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. |
NCT03804944 |
Converting HR+ Breast Cancer Into an Individualized Vaccine |
NCT05952557 |
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) |
NCT03090165 |
Ribociclib and Bicalutamide in AR+ TNBC |
NCT05307705 |
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
NCT05143229 |
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer |
NCT03572374 |
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job |
NCT05163223 |
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer |
NCT05570253 |
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer |
NCT04906395 |
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer |
NCT05852691 |
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
NCT05203445 |
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer |
NCT04849364 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer |
NCT05646862 |
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy |
NCT05455619 |
Evexomostat Plus Alpelisib and Fulvestrant in Women With the PIK3CA Mutation With HR+/Her2- Breast Cancer |
NCT06110793 |
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer |
NCT03255577 |
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer |
NCT04606030 |
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) |
NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
NCT06099769 |
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
NCT05207709 |
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype |
NCT06001762 |
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer |
NCT06105632 |
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment |
NCT05696626 |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
NCT05894239 |
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
NCT04961996 |
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) |
NCT04829604 |
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) |
NCT05879926 |
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 |
NCT05963997 |
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer |
NCT04873362 |
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
NCT05705401 |
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer |
NCT06075953 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment |
NCT05633654 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
NCT05840211 |
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy |
NCT03412643 |
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling |
NCT05949021 |
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer |
NCT04443348 |
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
NCT04588545 |
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
NCT03975647 |
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
NCT05963984 |
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants |
NCT03988595 |
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer |
NCT04852887 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
NCT05113251 |
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer |
NCT05296798 |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
NCT04893109 |
ATEMPT 2.0: Adjuvant T-DM1 vs TH |
NCT06065748 |
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
NCT05176756 |
RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR) |
NCT02778685 |
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer |
NCT04187898 |
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer |
NCT05306340 |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
NCT02993068 |
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) |
NCT05573126 |
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer |
NCT03095352 |
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease |
NCT05896189 |
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors |
NCT05483491 |
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer |
NCT03930680 |
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane |
NCT05747794 |
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy |
NCT05514054 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
NCT05382286 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT05382299 |
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT01766297 |
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer |
NCT06016725 |
Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial |
NCT05716893 |
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer |
NCT04983875 |
Mammography and Breast Arterial Calcification: An Information-Sharing Trial |
NCT04683679 |
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer |
NCT04669301 |
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II |
NCT05146297 |
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials |
NCT03742102 |
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer |
NCT03879629 |
TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol |
NCT05653752 |
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer |
NCT05721248 |
STOP-HER2: Stopping Trastuzumab in HER2+ MBC |
NCT05545150 |
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study |
NCT05467891 |
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
NCT06315296 |
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer |
NCT05554354 |
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial |
NCT05323955 |
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
NCT02276443 |
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative |
NCT05568472 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study |
NCT04090398 |
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones |
NCT03606967 |
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer |
NCT05890677 |
The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema |
NCT04468061 |
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC |
NCT05900986 |
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer |
NCT01570998 |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery |
NCT05076591 |
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors |
NCT06112613 |
Mobile Health for Adherence in Breast Cancer Patients |
NCT06157892 |
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors |
NCT06016738 |
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
NCT04389281 |
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma |
NCT05673200 |
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer |
NCT06058377 |
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
NCT04584255 |
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer |
NCT03562637 |
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC |
NCT05929768 |
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer |
NCT06037954 |
A Study of Mental Health Care in People With Cancer |
NCT05587972 |
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring |
NCT04150042 |
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells |
NCT04975308 |
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
NCT02912312 |
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer |
NCT05262400 |
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors |
NCT04569747 |
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
NCT03463954 |
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
NCT05372640 |
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
NCT06144164 |
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer |
NCT06246968 |
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer |
NCT04425018 |
MARGetuximab Or Trastuzumab (MARGOT) |
NCT03598257 |
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer |
NCT04549571 |
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions |
NCT03367572 |
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
NCT05694364 |
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies |
NCT04553770 |
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
NCT02620852 |
Women Informed to Screen Depending on Measures of Risk (Wisdom Study) |
NCT06023576 |
A Study of Blood Pressure Control During Cancer Treatment |
NCT03723928 |
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer |
NCT04197687 |
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery |
NCT02488967 |
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
NCT04711109 |
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation |
NCT04899908 |
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases |
NCT05216432 |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer |
NCT04871516 |
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer |
NCT04647916 |
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
NCT03971409 |
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
NCT06120283 |
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
NCT03418961 |
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer |
NCT04457596 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
NCT02945579 |
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer |
NCT05161195 |
Roll-over Study to Allow Continued Access to Ribociclib |
NCT05645380 |
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC |
NCT05812807 |
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
NCT05508906 |
Phase 1b Combo w/ Ribociclib and Alpelisib |
NCT05910294 |
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer |
NCT05301114 |
Social Risk Factors and Discrimination in Cancer Survivorship |
NCT05720039 |
Robotic vs. Open NSM for Early Stage Breast Cancer |
NCT05144698 |
RAPA-201 Therapy of Solid Tumors |
NCT06052852 |
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies |
NCT06171789 |
PRO1107 in Patients With Advanced Solid Tumors |
NCT04616248 |
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors |
NCT05269381 |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors |
NCT05076760 |
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer |
NCT04673448 |
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer |
NCT05534438 |
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer |
NCT03428802 |
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability |
NCT03524430 |
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy |
NCT05386108 |
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer |
NCT04771520 |
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors |
NCT04282044 |
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies |
NCT03996265 |
Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors |
NCT03401385 |
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) |
NCT04266249 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
NCT06103669 |
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) |
NCT05967533 |
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors |
NCT04084730 |
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer |
NCT04982926 |
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer |
NCT05514717 |
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 |
NCT05556473 |
F-Tryptophan PET/CT in Human Cancers |
NCT06299163 |
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors |
NCT05232916 |
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects |
NCT05113927 |
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. |
NCT04837820 |
The Effect of Acupuncture on Cancer-Related Cognitive Difficulties |
NCT04621721 |
Home-Based Physical Activity Intervention for Taxane-Induced CIPN |
NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
NCT03351348 |
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control |
NCT04766190 |
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer |
NCT04692831 |
Testing a New Imaging Agent to Identify Cancer |
NCT05715255 |
Adaptive Symptom Self-Management Immunotherapy Study |
NCT04763915 |
Improving Care After Inherited Cancer Testing |
NCT04541381 |
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care |
NCT03937154 |
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer |
NCT04751435 |
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients |
NCT05215769 |
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer |
NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
NCT04331535 |
The Genomic Medicine at VA Study |
NCT05751668 |
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) |
NCT05490472 |
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors |
NCT03011684 |
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
NCT04964934 |
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) |
NCT05677048 |
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention |
NCT05868226 |
PRE-I-SPY Phase I/Ib Oncology Platform Program |
NCT05765851 |
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |
NCT05768139 |
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
NCT05225428 |
Video Education With Result Dependent dIsclosure |
NCT05000294 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
NCT05969860 |
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
NCT04475640 |
Cancer Genetic Testing in Ethnic Populations |
NCT05453825 |
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors |
NCT05837598 |
Adapting the Tumor Board Model for Mental Illness and Cancer |
NCT05721976 |
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study |
NCT05458284 |
The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment |
NCT04042701 |
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
NCT04319757 |
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors |
NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
NCT02993159 |
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast |
NCT05465408 |
Culturally Aware AET Non-Initiation Intervention |
NCT05559164 |
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted |
NCT06334432 |
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors |
NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
NCT04147494 |
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues |
NCT05593094 |
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors |
NCT03435952 |
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT |
NCT04967976 |
Breast Mesh Used in Two-staged Breast Reconstruction |
NCT04650256 |
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences |
NCT06188520 |
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors |
NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
NCT03504488 |
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
NCT05871008 |
Integrated Actionable Aging Assessment for Cancer Patients Pilot |
NCT05162846 |
Methods for Increasing Genetic Testing Uptake in Michigan |
NCT02694809 |
The PROMISE Study: Duavee in Women With DCIS |
NCT04570956 |
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ |
NCT04496739 |
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) |
NCT05056077 |
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) |
NCT06253520 |
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer |
NCT04553133 |
PF-07104091 as a Single Agent and in Combination Therapy |
NCT06184867 |
Choices About Genetic Testing And Learning Your Risk With Smart Technology |
NCT05226871 |
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies |
NCT03412877 |
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer |
NCT05848739 |
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors |
NCT03740256 |
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors |
NCT05313191 |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors |
NCT03960463 |
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds |
NCT04072393 |
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers |
NCT04038619 |
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients |
NCT04294628 |
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer |
NCT06165419 |
Definitive Radiation for High-Risk Spine Metastases |
NCT05989724 |
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors |
NCT06180460 |
CALM: Managing Distress in Malignant Brain Cancer |
NCT04119024 |
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma |
NCT04589468 |
Researching the Effect of Exercise on Cancer |
NCT05735080 |
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer |
NCT06264921 |
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors |
NCT05082610 |
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab |
NCT05180474 |
GEN1047 for Solid Tumors - First in Human (FIH) Trial |
NCT04722692 |
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ |
NCT03233191 |
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer |
NCT05692960 |
Women's Interventions for Sexual Health: WISH |
NCT05595213 |
Wrist Cooling for Hot Flashes Clinical Trial |
NCT04606446 |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
NCT04593277 |
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study |
NCT05274451 |
A Study to Investigate LYL797 in Adults With Solid Tumors |
NCT05830097 |
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors |
NCT05283330 |
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors |
NCT05252416 |
(VELA) Study of BLU-222 in Advanced Solid Tumors |
NCT04706962 |
TH1902 in Patients With Advanced Solid Tumors |
NCT06022029 |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. |
NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
NCT04925284 |
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) |
NCT05579366 |
PRO1184 for Advanced Solid Tumors |
NCT05252390 |
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
NCT05123482 |
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies |
NCT06065059 |
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors |
NCT05650879 |
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer |
NCT05377996 |
A Study of XMT-1660 in Participants With Solid Tumors |
NCT05939440 |
Interventions to Decrease Financial Toxicity |
NCT06084481 |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
NCT04787042 |
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 |
NCT04557449 |
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors |
NCT05565417 |
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas |
NCT05511844 |
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors |
NCT03746431 |
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection |
NCT05864144 |
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
NCT03568656 |
Study to Evaluate CCS1477 in Advanced Tumours |
NCT05194072 |
A Study of SGN-B7H4V in Advanced Solid Tumors |
NCT05349227 |
Comprehensive Outcomes for After Cancer Health |
NCT04494945 |
Identifying and Caring for Individuals With Inherited Cancer Syndrome |
NCT02632448 |
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer |
NCT05891171 |
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
NCT05585034 |
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors |
NCT05837767 |
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue |
NCT05932862 |
Study of XL309 (ISM3091) in Patients With Advanced Solid Tumors |
NCT04478279 |
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors |
NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
NCT04278144 |
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
NCT06238479 |
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors |
NCT04704661 |
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
NCT04561362 |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies |
NCT06218303 |
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ |
NCT05218044 |
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ |
NCT05902988 |
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer |
NCT04588246 |
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery |
NCT05086692 |
A Beta-only IL-2 ImmunoTherapY Study |
NCT05787587 |
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
NCT05107674 |
A Study of NX-1607 in Adults With Advanced Malignancies |
NCT05208762 |
A Study of SGN-PDL1V in Advanced Solid Tumors |
NCT05544929 |
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers |
NCT05108298 |
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials |
NCT04644068 |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies |
NCT04895709 |
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
NCT03832855 |
Assessing the Immunogenicity of pING-hHER3FL |
NCT02872025 |
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) |
NCT05877599 |
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation |
NCT04067726 |
RANKL Inhibition and Mammographic Breast Density |
NCT04258813 |
Onco-primary Care Networking to Support TEAM-based Care |
NCT04389632 |
A Study of SGN-B6A in Advanced Solid Tumors |
NCT03556228 |
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma |
NCT04450732 |
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors |
NCT05576077 |
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors |
NCT05007106 |
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) |
NCT05827614 |
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications |
NCT05708950 |
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) |
NCT02928978 |
Ruxolitinib for Premalignant Breast Disease |
NCT05703269 |
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy |
NCT03075072 |
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial |
NCT05239143 |
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors |
NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
NCT05035407 |
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers |
NCT05215574 |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors |
NCT05070247 |
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
NCT03129139 |
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors |
NCT05887492 |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
NCT05259696 |
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) |
NCT04913337 |
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
NCT05500508 |
Oral AMXT 1501 Dicaprate in Combination With IV DFMO |
NCT04585750 |
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
NCT04152499 |
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
NCT04140526 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC |
NCT05683418 |
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors |
NCT04969835 |
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours |
NCT04768868 |
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
NCT05898399 |
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients |
NCT04712721 |
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. |
NCT06270706 |
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
NCT05712889 |
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer |
NCT03899792 |
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors |
NCT03157128 |
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) |
NCT05150691 |
A Study of DB-1303 in Advanced/Metastatic Solid Tumors |
NCT02264678 |
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents |
NCT02000089 |
The Cancer of the Pancreas Screening-5 CAPS5)Study |
NCT04890613 |
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation |
NCT05941507 |
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors |
NCT04225117 |
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) |
NCT04931823 |
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors |
NCT05888831 |
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors |
NCT05417594 |
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies |
NCT05785741 |
A Study of DB-1310 in Advanced/Metastatic Solid Tumors |
NCT04373564 |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
NCT05238922 |
Study of INCB123667 in Subjects With Advanced Solid Tumors |
NCT04300556 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |
NCT04143711 |
Study of DF1001 in Patients With Advanced Solid Tumors |
NCT05277051 |
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
NCT05325866 |
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression |
NCT05537740 |
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors |
NCT03821935 |
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors |
NCT05958199 |
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 |
NCT05297734 |
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer |